Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts
Home
Publications
Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts
Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts
Authors:
VM
V. Moreno
V. Moreno
MG
M. Gil-Martin
M. Gil-Martin
MJ
M. Johnson
M. Johnson
RA
R. Aljumaily
R. Aljumaily
ML
M.P. Lopez-Criado
M.P. Lopez-Criado
DN
D. Northfelt
D. Northfelt
MC
M. Crittenden
M. Crittenden
SJ
S. Jabbour
S. Jabbour
LR
L. Rosen
L. Rosen
EC
E. Calvo
E. Calvo
KP
K. Papadopoulos
K. Papadopoulos
PG
P. Garrido
P. Garrido
See more
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Publisher website
Google Scholar
1 October 2018
journal article
abstracts
Published by
Elsevier
in
Journal of Thoracic Oncology
Vol. 13
(10)
,
S366
DOI:
10.1016/j.jtho.2018.08.340
Abstract
No abstract available
Keywords
CEMIPLIMAB
ANTI-PD-1
NSCLC
Cited
Cited by 16 articles
Scroll to top